Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SELE | P16581 | 18/20 | 0.69 |
| ▸ | SELP | P16109 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14823276 | 0.96 | SELE (0.71) | SELESELP | |
| SCHEMBL16257568 | 0.93 | SELE (0.60) | SELESELP | |
| SCHEMBL13657266 | 0.92 | SELE (0.65) | SELESELP | |
| SCHEMBL15214014 | 0.91 | SELE (0.65) | SELESELP | |
| SCHEMBL13312082 | 0.89 | SELE (0.62) | SELESELP | |
| SCHEMBL14558013 | 0.88 | SELE (0.61) | SELESELP | |
| SCHEMBL13295107 | 0.88 | SELE (0.61) | SELESELP | |
| SCHEMBL15488911 | 0.88 | SELE (0.62) | SELESELP | |
| SCHEMBL15434745 | 0.88 | SELE (0.59) | SELESELP | |
| SCHEMBL13657365 | 0.88 | SELE (0.56) | SELESELP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150051164-A1 | PAN-SELECTIN INHIBITOR WITH ENHANCED PHARMACOKINETIC ACTIVITY | GLYCOMIMETICS INC (US) | 2015-02-19 | — | — | US | disclosed |
| US-8895510-B2 | Pan-selectin inhibitor with enhanced pharmacokinetic activity | GLYCOMIMETICS, INC. (US) | 2014-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150051164-A1 | PAN-SELECTIN INHIBITOR WITH ENHANCED PHARMACOKINETIC ACTIVITY | SELPLG, SELP, SELE | SELE 3/4885SELP 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.